Pulmonary vasodilator therapy in sarcoidosis‐associated pulmonary hypertension may decrease lung function decline and mortality

Abstract The efficacy of treating sarcoidosis‐associated pulmonary hypertension (SAPH) with pulmonary vasodilator therapy is unclear. The INCREASE trial showed improvement in 6‐minute walk distance (6MWD) and in decline in functional vital capacity (FVC) in patients with interstitial lung disease an...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Shameek Gayen, Sohaib Ansari, Bilal H. Lashari, Huaqing Zhao, Gerard J. Criner, Rohit Gupta, Albert James Mamary
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2023-04-01
Saila:	Pulmonary Circulation
Gaiak:	functional vital capacity lung transplant pulmonary hypertension pulmonary vasodilator therapy sarcoidosis
Sarrera elektronikoa:	https://doi.org/10.1002/pul2.12245
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!